Howat D W, Chand N, Braquet P, Willoughby D A
Department of Experimental Pathology, St. Bartholomew's Hospital Medical College, London, UK.
Agents Actions. 1989 Jun;27(3-4):473-6. doi: 10.1007/BF01972856.
Rats developing experimental allergic encephalomyelitis have been treated with intra-venous injections of Platelet-Activating Factor on days 5, 6 and 7 post adjuvant injection. Other rats have been treated with one of two different PAF antagonists or vehicle. The animals injected with PAF on day 5 post adjuvant developed a more severe form of the disease at an earlier time point than did control animals. Animals treated with the PAF antagonists did not develop the disease to any great extent. Treatment with the vehicle had no effect compared to control. These results implicate PAF in the aetiology of this model of multiple sclerosis and may suggest a role for PAF antagonists in the treatment of this disease.
在佐剂注射后第5、6和7天,对患实验性变应性脑脊髓炎的大鼠进行静脉注射血小板活化因子治疗。其他大鼠用两种不同的血小板活化因子拮抗剂之一或赋形剂进行治疗。在佐剂注射后第5天注射血小板活化因子的动物,比对照动物在更早的时间点出现了更严重的疾病形式。用血小板活化因子拮抗剂治疗的动物在很大程度上未患该病。与对照相比,用赋形剂治疗没有效果。这些结果表明血小板活化因子在这种多发性硬化症模型的病因学中起作用,并且可能提示血小板活化因子拮抗剂在这种疾病的治疗中具有一定作用。